The National Medical Products Administration conditionally approved the marketing of Trastuzumab for injection
May 31, 2025
Source: drugdu
66
According to the website of the National Medical Products Administration, the National Medical Products Administration has recently conditionally approved the marketing of Ruikang Trastuzumab for Injection (trade name: Avida) submitted by Suzhou Shengdia Biopharmaceutical Co., Ltd. through the priority review and approval procedure. The single drug is suitable for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have received at least one systemic treatment in the past. The launch of this product provides a new treatment option for related patients.
https://finance.eastmoney.com/a/202505293418294646.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
